A recent prospective study including patients treated with chemotherapy only has demonstrated that KIT mutations in exon 17 are prognostic factor in AML with RUNX1/RUNX1T1 after evaluating all types of KIT mutations [8]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.